In the modern life sciences landscape, the pressure on pharmacovigilance (PV) teams is reaching a critical inflection point. As pharmaceutical pipelines grow more complex and global regulatory bodies demand increasingly granular safety data, the industry is discovering that traditional, task-based automation is no longer sufficient. According to the Deloitte 2026 Life Sciences Outlook, nearly half of industry executives identify the adoption of advanced digital analytics as a primary driver of organizational change, with 30% specifically highlighting "agentic AI" as the next frontier for safety operations.
The industry is moving away from the era of simple robotic process automation (RPA) and into a new phase: decision intelligence. This shift promises to transition PV professionals from "data gatherers" to "scientific evaluators," fundamentally altering how risk is assessed and how patient safety is maintained.
The Evolution of Pharmacovigilance: A Chronology of Change
The Era of Manual Stewardship (Pre-2010s)
For decades, pharmacovigilance was defined by human-centric manual labor. Teams spent the vast majority of their time on document retrieval, manual data entry, and basic intake form standardization. While this ensured a high level of human oversight, it was inherently slow, prone to human error, and highly susceptible to bottlenecks whenever clinical trial volume surged.
The Rise of Transactional Automation (2015–2023)
The first significant modernization wave focused on "doing things faster." By implementing RPA, organizations successfully offloaded repetitive, transactional tasks to machines. This period saw the standardization of case intake and the automation of basic data entry. While this provided much-needed relief to exhausted teams, it did not fundamentally improve the quality of decision-making. The "human-in-the-loop" was still required to perform the heavy lifting of context gathering, meaning that while the data moved faster, the expert analysis remained trapped in legacy workflows.
The Agentic AI Transition (2024–Present)
Today, we are witnessing the third wave: the move toward agentic AI. Unlike previous iterations that merely performed a discrete task, agentic AI acts as a digital colleague. It is designed to orchestrate complex workflows by connecting disparate data silos—from literature reviews and real-world evidence (RWE) to internal clinical databases—thereby providing a comprehensive, contextualized package of information for the human expert to evaluate.
The Bottleneck: Why "Automating Tasks" Isn’t Enough
The fundamental flaw in many current PV strategies is the narrow view that AI should only be used to automate individual tasks. When organizations silo their AI deployments to specific, narrow functions, they create a "performance ceiling."
The real friction in pharmacovigilance doesn’t lie in the act of filling out a form; it lies in the assembly of the evidence required to make a life-altering safety decision. Safety teams are currently forced to navigate disconnected systems—regulatory databases, internal operational systems, and literature repositories—to gather the context needed to evaluate a potential signal.
Updesh Dosanjh, Practice Leader for Pharmacovigilance Technology Solutions at IQVIA, notes that the current operating model often forces experts to spend more time "searching for information" than applying the scientific rigor for which they were hired. When data environments are fragmented, the "time-to-decision" balloons, slowing down regulatory reporting and potentially delaying critical safety interventions.
Supporting Data: Efficiency and Precision at Scale
The shift toward decision intelligence is not merely a theoretical exercise; it is delivering measurable results for early adopters.
- Increased Throughput: Organizations that have moved beyond basic automation to AI-supported workflows have reported up to a 40% increase in reporting throughput without the need to expand their headcount.
- Compression of Timelines: Through the integration of AI-assisted evidence gathering, some firms have reduced the total duration of a case from company receipt to final submission to under two hours.
- Precision and Accuracy: In real-world applications, such as IQVIA’s Vigilance Detect, technology has achieved up to 94% precision and 99% accuracy in audio review, leading to an 81% reduction in manual review time for clinical trials.
- High-Volume Submission: Many leading firms are now reporting that more than 96% of their cases move through automated, AI-assisted submission pathways, proving that high-quality, regulated work can be handled by intelligent systems with the right human guardrails.
Official Perspectives: Rethinking the Human Role
The transition to AI-assisted intelligence requires more than just new software; it requires a fundamental overhaul of governance, internal readiness, and escalation protocols.
"The industry conversation is shifting from ‘Do we need AI?’ to ‘How can we deploy it responsibly while preserving scientific rigor and regulatory trust?’" says Dosanjh.
The Governance Challenge
Internal teams are often hesitant to adopt broad AI integration not because they doubt the technology’s potential, but because they lack confidence in the consistency of AI outputs. Organizations are learning that internal readiness must be the priority. This means developing:
- Contextual Consistency: AI cannot transform unstructured document data into structured safety reports without a deep understanding of scientific context.
- Escalation Paths: When an AI agent encounters an anomaly it cannot resolve, there must be a clear, documented path for immediate human intervention.
- Human-in-the-Loop Architecture: The most effective models are those where the AI serves as an orchestrator, compiling the data package, while the human expert remains the final arbiter of clinical significance and regulatory action.
The Strategic Implications: Decision Velocity as a Competitive Advantage
The future of pharmacovigilance is defined by "decision velocity"—the speed and accuracy with which an organization can turn raw data into a validated safety insight. As portfolios expand, the companies that will lead are those that can effectively orchestrate their data ecosystems.
Implications for Regulatory Compliance
Regulators are increasingly expecting real-time data transparency. Traditional manual workflows are struggling to meet these expectations, leading to backlogs. By shifting to decision intelligence, organizations are better positioned to meet compliance deadlines, as the AI system ensures that all relevant data points—even those from obscure literature or external databases—are accounted for before the final review.
Implications for Clinical Development
The ability to identify safety signals faster has a direct impact on the clinical pipeline. By reducing the noise and surfacing true signals earlier, AI allows drug developers to make better-informed decisions about trial progression or safety protocol modifications, potentially saving millions in development costs and accelerating time-to-market for life-saving therapies.
Conclusion: The Path Forward
The narrative of pharmacovigilance is being rewritten. While the initial focus was on the machine "doing the work," the focus is now on the machine "empowering the expert."
For the modern PV organization, success will be determined by three pillars:
- Integration: Moving away from fragmented, siloed data environments toward unified platforms that facilitate holistic analysis.
- Orchestration: Using AI not just for tasks, but for managing the workflow of evidence-gathering across the entire organization.
- Human-Centricity: Ensuring that every technological advancement is designed to elevate, rather than replace, the scientific expertise of the pharmacovigilance professional.
As Updesh Dosanjh highlights, the ultimate goal of these tools is to liberate the safety professional from the drudgery of information retrieval. In this new landscape, the human-in-the-loop remains the most critical component of the pharmacovigilance chain, but they will finally have the tools to ensure that their expertise is applied exactly where it is needed most—protecting patient safety with greater speed, intelligence, and confidence than ever before.
The transition is no longer optional; as the complexity of global health data continues to grow, the organizations that master AI-assisted decision intelligence will be the ones that define the future of the life sciences industry.
About the Author
